Adverum Biotechnologies to Present at the 2016 Ophthalmology Innovation Summit
Adverum Biotechnologies, a gene therapy company committed to discovering and developing novel medicines, announced that Dr. Samuel Barone, MD, Senior Vice President, Clinical Development will provide a brief corporate overview and data presentation today.
The presentation is now available on the Company’s website at www.adverumbio.com.
About Adverum Biotechnologies, Inc.
Adverum is a gene therapy company committed to discovering and developing novel medicines that can offer life-changing benefits to patients living with rare diseases or diseases of the eye who currently have limited or burdensome treatment options. Adverum has a robust pipeline that includes product candidates to treat wet AMD, A1AT deficiency, and hereditary angioedema, among other diseases. We are leveraging our next-generation adeno-associated virus (AAV)-based directed evolution platform to generate product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our focus on the patient is supported by clinical development expertise and core capabilities in vector optimization, process development, manufacturing, and assay development. For more information please visit www.adverumbio.com
Contact for Adverum: Tricia Truehart Vice President The Trout Group LLC 646-378-2953 ttruehart@troutgroup.com
other press releases by Adverum Biotechnologies, Inc.
Menlo Park, California, UNITED STATES
Contact for Adverum: Tricia Truehart Vice President The Trout Group LLC 646-378-2953 ttruehart@troutgroup.com
Adverum Biotechnologies, Inc. Logo
LOGO URL | Copy the link below
Formats available: